Literature DB >> 27443170

How generalizable are the SEER registries to the cancer populations of the USA?

Tzy-Mey Kuo1, Lee R Mobley2.   

Abstract

BACKGROUND: We determined whether the current SEER registries are representative of the nation's cancer cases or the socio-demographic characteristics.
METHODS: We used breast cancer (BC) and colorectal cancer (CRC) cases diagnosed 2004-2009 from the US Cancer Statistics (USCS) database. Cases were classified into groups residing in SEER coverage areas and the other areas. We compared difference between SEER and non-SEER areas in: age-race-specific proportions of late-stage BC or CRC, area demographics and socioeconomic factors, and data quality.
RESULTS: For late-stage CRC diagnosis, SEER areas contained lower proportions of people with other race and higher proportions of Asian and Hispanic females aged <40, than non-SEER areas. For late-stage BC diagnosis, SEER and non-SEER estimates were comparable. SEER areas had lower percentages of whites and higher percentages of young people, were more urban, and had higher percentage of poor, lower educational attainment, and higher unemployment. SEER areas also tended to have a higher percentage of case completeness than non-SEER areas.
CONCLUSION: Overall, SEER registries were not significantly different from non-SEER areas in terms of average age-race-specific proportions of late-stage BC or CRC, except for estimates of late-stage CRC for other race and young Asian and Hispanic women. Although case completeness was better in SEER areas than non-SEER areas, SEER areas had greater economic disadvantage and greater minority diversity among the population. This study demonstrated a need for caution in using SEER data and discussed advantages of using the more complete USCS database.

Entities:  

Keywords:  Cancer; Generalizable; Late stage; Registry; SEER

Mesh:

Year:  2016        PMID: 27443170      PMCID: PMC5180598          DOI: 10.1007/s10552-016-0790-x

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  14 in total

1.  Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.

Authors:  Joan L Warren; Carrie N Klabunde; Deborah Schrag; Peter B Bach; Gerald F Riley
Journal:  Med Care       Date:  2002-08       Impact factor: 2.983

2.  Descriptive epidemiology of colorectal cancer in the United States, 1998-2001.

Authors:  Jeannette Jackson-Thompson; Faruque Ahmed; Robert R German; Sue-Min Lai; Carol Friedman
Journal:  Cancer       Date:  2006-09-01       Impact factor: 6.860

3.  Generalizability of the surveillance, epidemiology, and end results registry population: factors relevant to epidemiologic and health care research.

Authors:  A B Nattinger; T L McAuliffe; M M Schapira
Journal:  J Clin Epidemiol       Date:  1997-08       Impact factor: 6.437

4.  How representative are the surveillance, epidemiology, and end results (SEER) program cancer data of the United States?

Authors:  Ray M Merrill; Kirk A Dearden
Journal:  Cancer Causes Control       Date:  2004-12       Impact factor: 2.506

5.  Geographic disparities in late-stage breast cancer diagnosis in California.

Authors:  Tzy-Mey Kuo; Lee R Mobley; Luc Anselin
Journal:  Health Place       Date:  2010-11-26       Impact factor: 4.078

6.  Surveillance of screening-detected cancers (colon and rectum, breast, and cervix) - United States, 2004-2006.

Authors:  S Jane Henley; Jessica B King; Robert R German; Lisa C Richardson; Marcus Plescia
Journal:  MMWR Surveill Summ       Date:  2010-11-26

7.  Geographic disparities in late-stage cancer diagnosis: multilevel factors and spatial interactions.

Authors:  Lee R Mobley; Tzy-Mey May Kuo; Lisa Watson; G Gordon Brown
Journal:  Health Place       Date:  2012-06-26       Impact factor: 4.078

8.  Colorectal cancer incidence in the United States, 1999-2004 : an updated analysis of data from the National Program of Cancer Registries and the Surveillance, Epidemiology, and End Results Program.

Authors:  Sun Hee Rim; Laura Seeff; Faruque Ahmed; Jessica B King; Steven S Coughlin
Journal:  Cancer       Date:  2009-05-01       Impact factor: 6.860

9.  A new method to evaluate the completeness of case ascertainment by a cancer registry.

Authors:  Barnali Das; Limin X Clegg; Eric J Feuer; Linda W Pickle
Journal:  Cancer Causes Control       Date:  2008-02-13       Impact factor: 2.506

10.  Building the infrastructure for nationwide cancer surveillance and control--a comparison between the National Program of Cancer Registries (NPCR) and the Surveillance, Epidemiology, and End Results (SEER) Program (United States).

Authors:  Phyllis A Wingo; Patricia M Jamison; Robert A Hiatt; Hannah K Weir; Paul M Gargiullo; Mary Hutton; Nancy C Lee; H Irene Hall
Journal:  Cancer Causes Control       Date:  2003-03       Impact factor: 2.506

View more
  33 in total

1.  United States Population-Based Estimates of Patient-Reported Outcomes Measurement Information System Symptom and Functional Status Reference Values for Individuals With Cancer.

Authors:  Roxanne E Jensen; Arnold L Potosky; Carol M Moinpour; Tania Lobo; David Cella; Elizabeth A Hahn; David Thissen; Ashley Wilder Smith; Jaeil Ahn; George Luta; Bryce B Reeve
Journal:  J Clin Oncol       Date:  2017-04-20       Impact factor: 44.544

2.  Ethnic Disparities in Imaging Utilization at Diagnosis of Non-Small Cell Lung Cancer.

Authors:  Rustain L Morgan; Sana D Karam; Cathy J Bradley
Journal:  J Natl Cancer Inst       Date:  2020-12-14       Impact factor: 13.506

3.  Update on triple-negative breast cancer disparities for the United States: A population-based study from the United States Cancer Statistics database, 2010 through 2014.

Authors:  Lia C Scott; Lee R Mobley; Tzy-Mey Kuo; Dora Il'yasova
Journal:  Cancer       Date:  2019-07-08       Impact factor: 6.860

4.  Utility and Generalizability of Multistate, Population-Based Cancer Registry Data for Rural Cancer Surveillance Research in the United States.

Authors:  Whitney E Zahnd; Wiley D Jenkins; Aimee S James; Sonya R Izadi; David E Steward; Amanda J Fogleman; Graham A Colditz; Laurent Brard
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-03-21       Impact factor: 4.254

5.  Rural representation of the surveillance, epidemiology, and end results database.

Authors:  Joshua Herb; Rachael Wolff; Philip McDaniel; Mark Holmes; Jennifer Lund; Karyn Stitzenberg
Journal:  Cancer Causes Control       Date:  2021-01-03       Impact factor: 2.506

Review 6.  Systematic review of the predictors of health service use in pancreatic cancer.

Authors:  Nadia N Khan; Tennille Lewin; Amy Hatton; Charles Pilgrim; Liane Ioannou; Luc Te Marvelde; John Zalcberg; Sue Evans
Journal:  Am J Cancer Res       Date:  2022-02-15       Impact factor: 6.166

7.  Disparities in the long-term survival of adolescent and young adult diffuse large B cell lymphoma survivors.

Authors:  Amy M Berkman; Clark R Andersen; Vidya Puthenpura; J A Livingston; Sairah Ahmed; Branko Cuglievan; Michelle A T Hildebrandt; Michael E Roth
Journal:  Cancer Epidemiol       Date:  2021-09-28       Impact factor: 2.984

8.  Survival after Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer.

Authors:  Alexander Melamed; Daniel J Margul; Ling Chen; Nancy L Keating; Marcela G Del Carmen; Junhua Yang; Brandon-Luke L Seagle; Amy Alexander; Emma L Barber; Laurel W Rice; Jason D Wright; Masha Kocherginsky; Shohreh Shahabi; J Alejandro Rauh-Hain
Journal:  N Engl J Med       Date:  2018-10-31       Impact factor: 91.245

9.  Adult Glioma Incidence and Survival by Race or Ethnicity in the United States From 2000 to 2014.

Authors:  Quinn T Ostrom; David J Cote; Mustafa Ascha; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  JAMA Oncol       Date:  2018-09-01       Impact factor: 31.777

10.  Geographic Disparities in Late-Stage Breast Cancer Diagnosis Rates and Their Persistence Over Time.

Authors:  Lee R Mobley; Florence K L Tangka; Zahava Berkowitz; Jacqueline Miller; Ingrid J Hall; Manxia Wu; Susan A Sabatino
Journal:  J Womens Health (Larchmt)       Date:  2021-04-29       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.